

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTAJHM1624

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 DEC 01 ChemPort single article sales feature unavailable
NEWS 3 JAN 06 The retention policy for unread STNmail messages
will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
Classification Data
NEWS 5 FEB 02 Simultaneous left and right truncation (SLART) added
for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7 FEB 06 Patent sequence location (PSL) data added to USGENE
NEWS 8 FEB 10 COMPENDEX reloaded and enhanced
NEWS 9 FEB 11 WTEXTILES reloaded and enhanced
NEWS 10 FEB 19 New patent-examiner citations in 300,000 CA/CAplus
patent records provide insights into related prior
art
NEWS 11 FEB 19 Increase the precision of your patent queries -- use
terms from the IPC Thesaurus, Version 2009.01
NEWS 12 FEB 23 Several formats for image display and print options
discontinued in USPATFULL and USPAT2
NEWS 13 FEB 23 MEDLINE now offers more precise author group fields
and 2009 MeSH terms
NEWS 14 FEB 23 TOXCENTER updates mirror those of MEDLINE - more
precise author group fields and 2009 MeSH terms
NEWS 15 FEB 23 Three million new patent records blast AEROSPACE into
STN patent clusters
NEWS 16 FEB 25 USGENE enhanced with patent family and legal status
display data from INPADOCDB
NEWS 17 MAR 06 INPADOCDB and INPAFAMDB enhanced with new display
formats
NEWS 18 MAR 11 EPFULL backfile enhanced with additional full-text
applications and grants
NEWS 19 MAR 11 ESBIOBASE reloaded and enhanced
NEWS 20 MAR 20 CAS databases on STN enhanced with new super role
for nanomaterial substances
NEWS 21 MAR 23 CA/CAplus enhanced with more than 250,000 patent
equivalents from China
NEWS 22 MAR 30 IMSPATENTS reloaded and enhanced
NEWS 23 APR 03 CAS coverage of exemplified prophetic substances
enhanced
NEWS 24 APR 07 STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:01:16 ON 08 APR 2009

FILE 'REGISTRY' ENTERED AT 11:01:48 ON 08 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 7 APR 2009 HIGHEST RN 1132879-07-2
DICTIONARY FILE UPDATES: 7 APR 2009 HIGHEST RN 1132879-07-2

New CAS Information Use Policies. enter HELP USAGETERMS for details..


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqgen/stndoc/properties.html>

=> Uploading C:\Program Files\Stnexp\Queries\10_series\10583796\10583796a.str



```
chain nodes :  
7 8 9 11 12 13 18  
ring nodes :
```

```

1 2 3 4 5 6
chain bonds :
3-9 4-7 5-8 9-11 11-12 12-13 13-18
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 3-9 4-5 4-7 5-6 5-8 9-11 11-12 12-13 13-18

```

G1:O,S

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 11:CLASS
12:CLASS 13:CLASS 18:Atom
Element Count :
Node 9: Limited
C,C4
N,N1


```

L1 STRUCTURE UPLOADED

```

=> d 11
L1 HAS NO ANSWERS
L1 STR

```



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

```

=> s 11
SAMPLE SEARCH INITIATED 11:02:09 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2720 TO ITERATE

```

```

73.5% PROCESSED 2000 ITERATIONS 5 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```

```


FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                      BATCH **COMPLETE**
PROJECTED ITERATIONS: 51272 TO 57528
PROJECTED ANSWERS: 5 TO 292

```

L2 5 SEA SSS SAM L1

=> d scan


L2 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-[4-[(4-fluorophenyl)methyl]-4,5-dihydro-
2-oxazolyl]-3-hydroxy-7-(4-morpholinylmethyl)-, sodium salt (1:1)
MF C23 H23 F N4 O4 . Na



● Na


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L2 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Imidazo[1,5-a]pyrimidin-4(6H)-one,
2-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-7,8-dihydro-3-hydroxy-8,8-
dimethyl-
MF C18 H17 F N4 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Pyridinecarboxamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-
1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]-
MF C23 H20 F N5 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN Carbamic acid, [1-[6-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,4-dihydro-5-hydroxy-4-oxo-2-pyrimidinyl]-1-methylethyl]-, phenylmethyl ester (9CI)
 MF C25 H23 F N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
 IN 4-Pyridinecarboxamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]-
 MF C23 H20 F N5 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s 11 full
 FULL SEARCH INITIATED 11:02:35 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 54486 TO ITERATE

100.0% PROCESSED 54486 ITERATIONS 90 ANSWERS
 SEARCH TIME: 00.00.01

L3 90 SEA SSS FUL L1

	SINCE FILE ENTRY	TOTAL SESSION
=> file caplus		
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	185.88	186.10

FILE 'CAPLUS' ENTERED AT 11:02:41 ON 08 APR 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Apr 2009 VOL 150 ISS 15
 FILE LAST UPDATED: 7 Apr 2009 (20090407/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13
L4 3 L3

=> d 14 1-3 ibib hitstr

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:804213 CAPLUS
DOCUMENT NUMBER: 149:128851
TITLE: Preparation of bicyclic pyrimidinones and analogues for the treatment of viral infections, particularly HIV infections
INVENTOR(S): Jones, Eric Dale; Coates, Jonathan Alan Victor; Rhodes, David Ian; Deadman, John Joseph; Vandegraaff, Nicholas Andrew; Winfield, Lisa Jane; Thienthong, Neeranat; Issa, William; Choi, Neil; MacFarlane, Katherine
PATENT ASSIGNEE(S): Avexa Limited, Australia
SOURCE: PCT Int. Appl., 168pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008077188	A1	20080703	WO 2007-AU1980	20071221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			AU 2006-907283	A 20061222
			AU 2007-902479	A 20070509
			AU 2007-903401	A 20070625
			AU 2007-904114	A 20070731

OTHER SOURCE(S): MARPAT 149:128851
IT 1036646-53-3P, 3-Hydroxy-7-methyl-2-(5-phenyloxazol-2-yl)pyrido[1,2-a]pyrimidin-4-one 1036646-56-6P, 2-[5-(4-Fluorophenyl)oxazol-2-yl]-3-hydroxy-7-methylpyrido[1,2-a]pyrimidin-4-one 1036646-57-7P, 2-[5-(4-Methoxyphenyl)oxazol-2-yl]-3-hydroxy-7-methylpyrido[1,2-a]pyrimidin-4-one 1036646-59-9P, 2-[5-(4-Fluorobenzyl)oxazol-2-yl]-3-hydroxy-7-methylpyrido[1,2-a]pyrimidin-4-one 1036646-60-2P, 3-Hydroxy-7-methyl-2-(5-phenylthiazol-2-yl)pyrido[1,2-a]pyrimidin-4-one 1036646-62-4P, 2-[5-(4-Fluorobenzyl)thiazol-2-yl]-3-hydroxy-7-methylpyrido[1,2-a]pyrimidin-4-one 1036646-63-5P, 2-[5-(3,4-Dichlorobenzyl)thiazol-2-yl]-3-hydroxy-7-methylpyrido[1,2-a]pyrimidin-4-one 1036646-64-6P,

2-[5-(4-Fluorobenzyl)thiazol-2-yl]-3-hydroxy-7-(morpholin-4-yl)pyrido[1,2-a]pyrimidin-4-one 1036646-65-7P,

2-[5-(3,4-Dichlorobenzyl)thiazol-2-yl]-3-hydroxy-7-(morpholin-4-yl)pyrido[1,2-a]pyrimidin-4-one 1036646-66-8P,

2-[5-(4-Fluorobenzyl)thiazol-2-yl]-3-hydroxy-7-[(morpholin-4-yl)methyl]pyrido[1,2-a]pyrimidin-4-one 1036647-85-4P,

2-[4-(4-Fluorobenzyl)-4,5-dihydrooxazol-2-yl]-3-hydroxy-7-(morpholin-4-yl)pyrido[1,2-a]pyrimidin-4-one Sodium Salt 1036647-88-7P,


2-[4-(4-Fluorobenzyl)-4,5-dihydrooxazol-2-yl]-3-hydroxy-7-[(morpholin-4-yl)methyl]pyrido[1,2-a]pyrimidin-4-one Sodium Salt

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic pyrimidinones and analogs for the treatment of viral infections, particularly HIV infections)


RN 1036646-53-3 CAPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-hydroxy-7-methyl-2-(5-phenyl-2-oxazolyl)- (CA INDEX NAME)




RN 1036646-56-6 CAPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-[5-(4-fluorophenyl)-2-oxazolyl]-3-hydroxy-7-methyl- (CA INDEX NAME)




RN 1036646-57-7 CAPLUS


CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-hydroxy-2-[5-(4-methoxyphenyl)-2-oxazolyl]-7-methyl- (CA INDEX NAME)




RN 1036646-59-9 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-3-hydroxy-7-methyl- (CA INDEX NAME)




RN 1036646-60-2 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 3-hydroxy-7-methyl-2-(5-phenyl-2-thiazolyl)- (CA INDEX NAME)



RN 1036646-62-4 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-3-hydroxy-7-methyl- (CA INDEX NAME)




RN 1036646-63-5 CAPLUS
CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-[5-[(3,4-dichlorophenyl)methyl]-2-thiazolyl]-3-hydroxy-7-methyl- (CA INDEX NAME)




RN 1036646-64-6 CAPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-3-hydroxy-7-(4-morpholinyl)- (CA INDEX NAME)




RN 1036646-65-7 CAPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-[5-[(3,4-dichlorophenyl)methyl]-2-thiazolyl]-3-hydroxy-7-(4-morpholinyl)- (CA INDEX NAME)




RN 1036646-66-8 CAPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-3-hydroxy-7-(4-morpholinylmethyl)- (CA INDEX NAME)




RN 1036647-85-4 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-[4-[(4-fluorophenyl)methyl]-4,5-dihydro-2-oxazolyl]-3-hydroxy-7-(4-morpholinyl)-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 1036647-88-7 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-[4-[(4-fluorophenyl)methyl]-4,5-dihydro-2-oxazolyl]-3-hydroxy-7-(4-morpholinylmethyl)-, sodium salt (1:1) (CA INDEX NAME)



● Na

IT 1036646-74-8P
 RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of bicyclic pyrimidinones and analogs for the treatment of viral infections, particularly HIV infections)
 RN 1036646-74-8 CAPLUS
 CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-[5-[(4-fluorophenyl)methyl]-2-

thiazolyl]-7-(4-morpholinylmethyl)-3-(phenylmethoxy)- (CA INDEX NAME)




IT 1036646-55-5P, 3-[(Benzyl)oxy]-7-methyl-2-(5-phenyloxazol-2-yl)pyrido[1,2-a]pyrimidin-4-one 1036646-61-3P,
3-[(Benzyl)oxy]-7-methyl-2-(5-phenylthiazol-2-yl)pyrido[1,2-a]pyrimidin-4-one 1036647-87-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of bicyclic pyrimidinones and analogs for the treatment of viral infections, particularly HIV infections)


RN 1036646-55-5 CAPPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 7-methyl-3-(phenylmethoxy)-2-(5-phenyl-2-oxazolyl)- (CA INDEX NAME)




RN 1036646-61-3 CAPPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 7-methyl-3-(phenylmethoxy)-2-(5-phenyl-2-thiazolyl)- (CA INDEX NAME)



RN 1036647-87-6 CAPPLUS

CN 4H-Pyrido[1,2-a]pyrimidin-4-one, 2-[4-[(4-fluorophenyl)methyl]-4,5-dihydro-2-oxazolyl]-3-[(methylsulfonyl)oxy]-7-(4-morpholinyl)- (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:588951 CAPLUS
 DOCUMENT NUMBER: 143:115559
 TITLE: Preparation of hydroxypyrimidinone derivatives as HIV integrase inhibitors
 INVENTOR(S): Mikamiyama, Hidenori; Iwata, Minako; Taoda, Yoshiyuki
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 124 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061490	A1	20050707	WO 2004-JP19048	20041221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1698628	A1	20060906	EP 2004-807405	20041221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
US 20070149556	A1	20070628	US 2006-583796	20060621
PRIORITY APPLN. INFO.:			JP 2003-423947	A 20031222
			WO 2004-JP19048	W 20041221


OTHER SOURCE(S): MARPAT 143:115559
 IT 857663-98-0P 857664-00-7P 857664-36-9P
 857664-55-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of hydroxypyrimidinone derivs. as HIV integrase inhibitors)
 RN 857663-98-0 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-(1-amino-1-methylethyl)-6-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-5-hydroxy-3-methyl- (CA INDEX NAME)



RN 857664-00-7 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-(1-amino-1-methylethyl)-6-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5-hydroxy- (CA INDEX NAME)




RN 857664-36-9 CAPLUS
 CN 4(3H)-Pyrimidinone, 6-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5-hydroxy-2-[1-methyl-1-(methylamino)ethyl]- (CA INDEX NAME)



RN 857664-55-2 CAPLUS

CN Imidazo[1,5-a]pyrimidin-4(6H)-one,
2-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-7,8-dihydro-3-hydroxy-8,8-
dimethyl- (CA INDEX NAME)



IT 857663-94-6P 857663-99-1P 857664-01-8P

857664-02-9P 857664-03-0P 857664-04-1P

857664-05-2P 857664-06-3P 857664-07-4P

857664-16-5P 857664-17-6P 857664-18-7P

857664-19-8P 857664-20-1P 857664-21-2P

857664-22-3P 857664-23-4P 857664-24-5P

857664-25-6P 857664-26-7P 857664-27-8P

857664-28-9P 857664-29-0P 857664-30-3P

857664-31-4P 857664-32-5P 857664-33-6P

857664-34-7P 857664-35-8P 857664-37-0P

857664-38-1P 857664-39-2P 857664-40-5P

857664-41-6P 857664-42-7P 857664-43-8P

857664-44-9P 857664-45-0P 857664-51-8P

857664-52-9P 857664-53-0P 857664-54-1P


857664-56-3P 857664-57-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of hydroxypyrimidinone derivs. as HIV integrase inhibitors)


RN 857663-94-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(4-bromophenyl)methyl]-6-[5-[(4-
fluorophenyl)methyl]-2-oxazolyl]-5-hydroxy-3-methyl- (CA INDEX NAME)




RN 857663-99-1 CAPLUS

CN Acetamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857664-01-8 CAPLUS

CN Acetamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)



RN 857664-02-9 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[1-(4-bromophenyl)-2-phenylethyl]-6-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-5-hydroxy-3-methyl- (CA INDEX NAME)



RN 857664-03-0 CAPLUS

CN 4(3H)-Pyrimidinone, 6-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-5-hydroxy-3-methyl-2-[(2S)-1-(methylsulfonyl)-2-pyrrolidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 857664-04-1 CAPLUS

CN 4(3H)-Pyrimidinone, 6-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-5-hydroxy-3-methyl-2-(2S)-2-pyrrolidinyl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 857664-05-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-[(2S)-1-acetyl-2-pyrrolidinyl]-6-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-5-hydroxy-3-methyl-, lithium salt (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● Li

RN 857664-06-3 CAPLUS
CN Acetamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857664-07-4 CAPLUS
CN 2-Pyridinecarboxamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857664-16-5 CAPLUS

CN 2-Pyridinecarboxamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857664-17-6 CAPLUS

CN 4-Pyridinecarboxamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857664-18-7 CAPLUS

CN Formamide, N-[1-[6-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,4-dihydro-5-hydroxy-4-oxo-2-pyrimidinyl]-1-methylethyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 857664-19-8 CAPLUS


CN Benzamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1-methylethyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]- (CA INDEX NAME)




RN 857664-20-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[1-[6-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,4-dihydro-5-hydroxy-4-oxo-2-pyrimidinyl]-1-methylethyl]- (9CI) (CA INDEX NAME)




RN 857664-21-2 CAPLUS
CN 2-Pyrazinecarboxamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857664-22-3 CAPLUS
CN Benzamide, 4-fluoro-N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)



RN 857664-23-4 CAPLUS
 CN Acetamide, 2-bromo-N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857664-24-5 CAPLUS
 CN Acetamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]-2-methoxy- (CA INDEX NAME)



RN 857664-25-6 CAPLUS


CN Acetamide, 2-chloro-N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)



RN 857664-26-7 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[(2S)-1-acetyl-2-pyrrolidinyl]-6-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 857664-27-8 CAPLUS

CN Methanesulfonamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857664-28-9 CAPLUS

CN Acetamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857664-29-0 CAPLUS


CN Acetamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]-1-methylethyl]-2-methoxy- (CA INDEX NAME)




RN 857664-30-3 CAPLUS
CN Pentanamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)



RN 857664-31-4 CAPLUS
CN Acetamide, 2-chloro-N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857664-32-5 CAPLUS
CN Cyclopropanecarboxamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857664-33-6 CAPLUS

CN Ethanediamide, N2-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]-1-methylethyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 857664-34-7 CAPLUS

CN 2-Propanesulfonamide, 2-chloro-N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857664-35-8 CAPLUS

CN Urea, N-ethyl-N'-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857664-37-0 CAPLUS


CN Acetamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]-N-methyl- (CA INDEX NAME)




RN 857664-38-1 CAPLUS
CN 2-Pyridinecarboxamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]-1-methylethyl]-N-methyl- (CA INDEX NAME)



RN 857664-39-2 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-bromophenyl)-6-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5-hydroxy- (CA INDEX NAME)




RN 857664-40-5 CAPLUS
CN Methanesulfonamide, N-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]phenyl- (CA INDEX NAME)




RN 857664-41-6 CAPLUS

CN Acetamide, N-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]phenyl]- (CA INDEX NAME)




RN 857664-42-7 CAPLUS

CN Acetamide, N-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]phenyl]-2-methoxy- (CA INDEX NAME)




RN 857664-43-8 CAPLUS

CN Ethanediamide, N2-[4-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-hydroxy-6-oxo-2-pyrimidinyl]phenyl]-N1,N1-dimethyl- (CA INDEX NAME)




RN 857664-44-9 CAPLUS

CN 4(3H)-Pyrimidinone, 6-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5-hydroxy-2-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 857664-45-0 CAPLUS

CN 4(3H)-Pyrimidinone, 6-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5-hydroxy-2-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (CA INDEX NAME)




RN 857664-51-8 CAPLUS

CN Imidazo[1,5-a]pyrimidin-4(6H)-one,
2-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-7,8-dihydro-3-hydroxy-7,8,8-
trimethyl- (CA INDEX NAME)




RN 857664-52-9 CAPLUS

CN Imidazo[1,5-a]pyrimidin-4(6H)-one,
2-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-7,8-dihydro-3-hydroxy-8,8-
dimethyl-6-phenyl- (CA INDEX NAME)




RN 857664-53-0 CAPLUS


CN Imidazo[1,5-a]pyrimidin-4(6H)-one,
7-ethyl-2-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-7,8-dihydro-3-hydroxy-
6,8,8-trimethyl- (CA INDEX NAME)




RN 857664-54-1 CAPLUS
 CN Imidazo[1,5-a]pyrimidin-4(6H)-one,
 2-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-7,8-dihydro-3-hydroxy-6,6,8,8-tetramethyl- (CA INDEX NAME)



RN 857664-56-3 CAPLUS
 CN Imidazo[1,5-a]pyrimidin-4(6H)-one,
 7-acetyl-2-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-7,8-dihydro-3-hydroxy-8,8-dimethyl- (CA INDEX NAME)



RN 857664-57-4 CAPLUS
 CN 4H-Pyrazino[1,2-a]pyrimidine-4,7(6H)-dione,
 2-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-8,9-dihydro-3-hydroxy-8,9,9-trimethyl- (CA INDEX NAME)




IT 857664-83-6P 857664-90-5P 857664-91-6P
 857664-92-7P 857664-95-0P 857664-97-2P
 857664-98-3P 857665-03-3P 857665-04-4P
 857665-05-5P 857665-17-9P 857665-18-0P
 857665-20-4P 857665-21-5P 857665-22-6P
 857665-23-7P 857665-24-8P 857665-25-9P
 857665-33-9P 857665-39-5P 857665-40-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of hydroxypyrimidinone derivs. as HIV integrase inhibitors)


RN 857664-83-6 CAPLUS

CN 4(3H)-Pyrimidinone, 2-[(4-bromophenyl)methyl]-6-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-3-methyl-5-(phenylmethoxy)- (CA INDEX NAME)




RN 857664-90-5 CAPLUS

CN Carbamic acid, [1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5-hydroxy-6-methoxy-2-pyrimidinyl]-1-methylethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 857664-91-6 CAPLUS

CN Carbamic acid, [1-[5-(acetyloxy)-4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-6-methoxy-2-pyrimidinyl]-1-methylethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 857664-92-7 CAPLUS

CN Carbamic acid, [1-[6-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,4-dihydro-5-hydroxy-4-oxo-2-pyrimidinyl]-1-methylethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 857664-95-0 CAPLUS


CN 4(3H)-Pyrimidinone, 2-[1-(4-bromophenyl)-2-phenylethyl]-6-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-3-methyl-5-(phenylmethoxy)- (CA INDEX NAME)



RN 857664-97-2 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 2-[4-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-1,6-dihydro-5-methoxy-1-methyl-6-oxo-2-pyrimidinyl]-, 1,1-dimethylethyl ester, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 857664-98-3 CAPLUS


CN 4 (3H)-Pyrimidinone, 6-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-5-hydroxy-3-methyl-2-(2S)-2-pyrrolidinyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 857665-03-3 CAPLUS

CN Acetamide, N-[1-[4-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-5,6-dimethoxy-2-pyrimidinyl]-1-methylethyl]- (CA INDEX NAME)




RN 857665-04-4 CAPLUS


CN Carbamic acid, [1-[4-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-6-methoxy-5-(phenylmethoxy)-2-pyrimidinyl]-1-methylethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 857665-05-5 CAPLUS
 CN 4(3H)-Pyrimidinone, 2-(1-amino-1-methylethyl)-6-[5-[(4-fluorophenyl)methyl]-2-oxazolyl]-5-hydroxy- (CA INDEX NAME)




RN 857665-17-9 CAPLUS
 CN Carbamic acid, [1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-5-methoxy-1-methyl-6-oxo-2-pyrimidinyl]-1-methylethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 857665-18-0 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(1-amino-1-methylethyl)-6-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5-hydroxy-3-methyl- (CA INDEX NAME)



RN 857665-20-4 CAPLUS
CN Carbamic acid, [1-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5,6-dimethoxy-2-pyrimidinyl]-1-methylethyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 857665-21-5 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-bromophenyl)-6-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5-methoxy- (CA INDEX NAME)




RN 857665-22-6 CAPLUS

CN Pyrimidine, 2-(4-bromophenyl)-4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5,6-dimethoxy- (CA INDEX NAME)




RN 857665-23-7 CAPLUS


CN Carbamic acid, [4-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5,6-dimethoxy-2-pyrimidinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 857665-24-8 CAPLUS
CN 4(3H)-Pyrimidinone, 2-(4-aminophenyl)-6-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5-hydroxy- (CA INDEX NAME)




RN 857665-25-9 CAPLUS
CN Morpholine, 4-[4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-5,6-dimethoxy-2-pyrimidinyl]phenyl- (CA INDEX NAME)




RN 857665-33-9 CAPLUS
CN Acetic acid, 2-chloro-, 2-[1-[(2-chloroacetyl)methylamino]-1-methylethyl]-4-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-1,6-dihydro-6-oxo-5-pyrimidinyl ester (CA INDEX NAME)



RN 857665-39-5 CAPLUS
CN Imidazo[1,5-a]pyrimidin-4(6H)-one,
7-acetyl-3-(acetoxy)-2-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-7,8-
dihydro-8,8-dimethyl- (CA INDEX NAME)



RN 857665-40-8 CAPLUS
CN Imidazo[1,5-a]pyrimidin-4(6H)-one,
3-(acetyloxy)-2-[5-[(4-fluorophenyl)methyl]-2-thiazolyl]-7,8-dihydro-8,8-
dimethyl- (CA INDEX NAME)



REFERENCE COUNT:


7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1996:186071 CAPLUS
 DOCUMENT NUMBER: 124:232485
 ORIGINAL REFERENCE NO.: 124:43075a, 43078a
 TITLE: Indole pyrimidinyl derivatives useful for the treatment of migraine
 INVENTOR(S): Del Castillo Nieto, Juan Carlos; Caldero Ges, Jose Maria; Roca Acin, Juan; Gimenez Guasch, Fernando; Bosch Rovira, Anna; Dalmases Barjoan, Pedro; Huguet Clotet, Juan; Marquillas, Olondriz Francisco
 PATENT ASSIGNEE(S): Vita-Invest, S.A., Spain
 SOURCE: PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Spanish
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9535293	A1	19951228	WO 1995-ES74	19950613
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ES 2079323	A1	19960101	ES 1994-1346	19940621
ES 2079323	B1	19961016		
CA 2169050	A1	19951228	CA 1995-2169050	19950613
AU 9526750	A	19960115	AU 1995-26750	19950613
EP 714896	A1	19960605	EP 1995-921844	19950613
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 09502205	T	19970304	JP 1995-501679	19950613
PRIORITY APPLN. INFO.:			ES 1994-1346	A 19940621
			WO 1995-ES74	W 19950613

OTHER SOURCE(S): MARPAT 124:232485
 IT 174728-35-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (indole pyrimidinyl derivs. useful for the treatment of migraine)
 RN 174728-35-9 CAPLUS
 CN 1H-Indole-5-methanesulfonamide, 3-[3-[(1-(5,6-dimethoxy-4-pyrimidinyl)-3-pyrrolidinyl]amino]propyl]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold
COST IN U.S. DOLLARS

SINCE FILE TOTAL

FULL ESTIMATED COST	ENTRY	SESSION
---------------------	-------	---------

14.67	200.77
-------	--------

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 11:06:04 ON 08 APR 2009